Targeting SIRT3 to treat aggressive B‑cell lymphomas
Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11266206
A new drug that blocks the SIRT3 protein to kill aggressive or treatment‑resistant diffuse large B‑cell lymphomas (DLBCL).
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11266206 on ClinicalTrials.gov |
What this research studies
If I had aggressive DLBCL, researchers would give a small drug that blocks SIRT3, a protein my tumor cells depend on, aiming to stop their growth. In lab‑grown lymphoma cells and in animal models this drug (called YC8‑02) disrupts how tumor cells use amino acids like glutamine and triggers destructive autophagy that kills them. The team would also try combining the SIRT3 blocker with existing drugs such as venetoclax or standard chemotherapy to see if combinations work better. They will study how resistance might develop and test ways to prevent it so the treatment could stay effective.
Who could benefit from this research
Good fit: Patients with aggressive or refractory diffuse large B‑cell lymphoma (DLBCL) or other treatment‑resistant B‑cell lymphomas would be the most likely candidates for related clinical trials.
Not a fit: People with non‑B‑cell cancers, indolent lymphomas, or tumors that do not rely on SIRT3 are unlikely to benefit from this therapy.
Why it matters
Potential benefit: If successful, this approach could become a new targeted therapy that kills aggressive or chemo‑resistant DLBCL tumors and may work across many genetic subtypes.
How similar studies have performed: Preclinical studies show the SIRT3 blocker YC8‑02 kills DLBCL cells in lab and animal models and boosts effects with venetoclax, but this approach has not yet been tested in humans.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, MENG — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: LI, MENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.